Sequential therapy in plaque psoriasis using the "Hit and Run" approach: Infliximab followed by efalizumab

International Journal of Dermatology

Volumn 51, Issue 2, 2012, Pages 236-237

  Penz, Séverine ^a   Pelletier, Fabien ^a   Riou Gotta, Marie Odile ^a   Puzenat, Eve ^a   Levang, Julien ^a   Mermet, Isabelle ^a   Humbert, Philippe ^a   Aubin, François ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

DRUG EFFICACY; HUMAN; LETTER; PSORIASIS VULGARIS; SCORING SYSTEM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84855978186     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04488.x     Document Type: Letter

References (2)

1. Barde C, Thielen AM, Saurat JH. Infliximab then efalizumab, the 'hit and run' approach does not work. Dermatology 2008; 216: 171-172.
2. Brunasso AM, Delfino C, Massone C. Efalizumab rebound response to a sequential therapy of infliximab followed by efalizumab. Dermatology 2009; 218: 73-74.